Lumexa Imaging Holdings (LMRI) Q2 FY26 earnings call: guidance and Q&A

What are the expectations for seasonality in H2 and what drivers will contribute to sequential ramp?

Management expects natural seasonality with 55% of earnings in H2, driven by sequential volume ramping and maturation of 2024/2025 de novo cohorts. Advanced imaging strength and new facilities also contribute.

“As we reported last quarter, we expected 45% of our earnings in the first half of the year and 55% in the back half, and we're right on that. That comes from the seasonal ramping of volume and the ramping of our de novos.”

asked by Brett Grulkowsk · answered by J. Martin

Provide color on HSS JV progress, future expansion, and the broader JV pipeline.

HSS JV is focusing on a de novo approach in New York metro area, with site plans advancing. The broader pipeline for health system partnerships is robust, with close to 100 health systems identified as potential partners due to unmet outpatient imaging needs and industry fragmentation.

“With HSS, similar to UPMC, we are focusing on a de novo approach. We've already targeted markets in the New York metropolitan area and actively advancing site plan.”

asked by Brett Grulkowsk · answered by Caitlin Zulla

Elaborate on payor mix shifts in some markets and observations on procedure mix (e.g., ortho-related vs. acute).

Payor mix shifts were slight and not significant, varying by market and not indicating a long-term trend. Procedure mix shows strength in MRI (7.2% growth system-wide) and PET (23.2% growth), with focus on expanding PET with new machines and tracers due to significant backlogs in communities.

“MRI growth on a system-wide basis was 7.2% quarter-over-quarter. So continuing to drive our focus on supporting MRI and then PET, so 23.2% growth, as we highlighted in the script.”

asked by Andrew Cooper · answered by Caitlin Zulla

Provide same-store system-wide revenue growth and its components, and clarify commercial mix trends.

Same-site system-wide revenue growth was 4.4%, composed of 2.2% volume growth and 2.2% rate growth. Consolidated commercial mix was 59%, same as last year, with only fractional and non-durable downward ticks in a few markets, unlike more significant shifts reported by hospitals.

“So same-site system-wide basis was 4.4% revenue and 2.2% volume, 2.2% rate.”

asked by Andrew Mok · answered by J. Martin

How will the proposed site neutrality rule impact growth opportunities, specifically if it will accelerate existing JV growth or create new types of opportunities?

The proposed rule is a multi-year catalyst that reinforces existing conversations about hospitals needing more imaging capacity. It improves the relative attractiveness of Lumexa's IDTF model, which does not rely on hospital outpatient reimbursement premiums. It's expected to increase urgency in the partnership pipeline and lead to new centers and expanded relationships, but Lumexa's strategy doesn't depend on its finalization.

“I see this as a multiyear catalyst versus something that's going to change our results immediately. What I do think it does is it -- today, it reinforces the conversations that are already happening that hospitals need more imaging capacity and building that capacity in a high-cost hospital setting is becoming increasingly difficult to justify.”

asked by Stephen Baxter · answered by Caitlin Zulla

Discuss Q2 cash flow from ops, and expectations for cash flow from ops and CapEx in H2.

Q2 cash flow was strong, supporting the 25-30% FCF conversion guidance for the year. Q2 benefited from timing of working capital swings and JV distributions. CapEx is expected to be $5 million to $7 million per quarter, potentially at the higher end if growth opportunities arise, but within the FCF guidance.

“Yes, we feel real good about what Q2 means for the guidance range we provided of 25% to 30% conversion rate. That translates to something like $60 million to $70 million of free cash flow for the year.”

asked by Pito Chickering · answered by J. Martin

How is Lumexa managing labor tightness for radiologists and techs, and are technologies like virtual MRI effectively backfilling capacity limitations?

Operating expenses for labor are up 5% YoY, which is considered good in the current inflationary environment. Lumexa uses the Technologist Advancement Academy, virtual MRI (allowing one tech to run multiple machines), and a 3-pronged radiologist model (Connexia telerad, third-party, affiliated physician groups) to manage capacity and meet demand.

“Yes, we look at our expense for this as like it's up 5% year-over-year. Our operating expenses from '25 to '26. And so in this kind of inflationary environment that we're in generally in the economy, that feels pretty good.”

asked by Benjamin Rossi · answered by J. Martin